Lab Anim Res.  2021 Sep;37(3):193-202. 10.1186/s42826-021-00093-1.

Acute and 28-days subacute toxicity studies of Gαq-RGS2 signaling inhibitor

• Beladiya JV
• Mehta AA

• KMID: 2521034
• DOI: http://doi.org/10.1186/s42826-021-00093-1

Abstract

Background
The aim of study was to evaluate the single oral dose and 28 day repeated oral administration toxicity profile of the synthetic compound Gαq-RGS2 signaling inhibitor, (1-(5-chloro-2-hydroxyphenyl)-3-(4-(trifluoromethyl)phenyl)-1 H-1,2,4-triazol-5(4 H)-one) as per OECD guideline 425 (2008a) and 407 (2008b), respectively.
Results
In acute toxicity study, a single oral dose administration of Gαq-RGS2 signaling inhibitor did not show any mortality at doses of 5, 50, 300 and 2000 mg/kg within 24 h and 14 days. The treatment of GαqRGS2 signaling inhibitor at dose 10 and 100 mg/kg for 28 days did not show any mortality, significant changes in the increase of body weight, various organ damage markers, hematological parameters, relative organ/body weight ratio and microscopic anatomical texture of essential organs as compared to vehicle and normal control.
Conclusions
A single oral administration of Gαq-RGS2 signaling inhibitor up to dose of 2000 mg/kg in mice and repeated administration of Gαq-RGS2 signaling inhibitor at higher dose 100 mg/kg for 28 days in the rats is safe.

Keyword

Acute toxicity; Sub-acute toxicity; Gαq-RGS2 signaling inhibitor; 28-days repeated dose toxicity; Single oral dose toxicity